Novartis raises 2023 forecast, maps out Sandoz spin-off

Novartis on Tuesday raised its full-year earnings forecast for the second time on strong drug sales and mapped out the planned separation and stock market debut of its generic medicines division Sandoz for early October.

Read the full article here

Related Articles